{"id":"W2588611749","doi":"10.1093/annonc/mdw371.108","title":"Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Hepatocellular carcinoma; Internal medicine; Adverse effect; Clinical endpoint; Progressive disease; Milan criteria; Oncology; Cancer; Surgery; Clinical trial; Liver transplantation; Transplantation; Disease; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001154881,0.0009277248,0.001825753,0.0002745772,0.0003649816,0.0009926996,0.0005875203,0.0007819952,0.002384722],"category_scores_gemma":[0.0008483835,0.0005086882,0.001502065,0.0003630527,0.0005183907,0.00100897,0.0004055278,0.002509715,0.0006427174],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009370517,"about_ca_system_score_gemma":0.001085283,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001155046,"about_ca_topic_score_gemma":0.002738602,"domain_scores_codex":[0.9997278,0.0001155829,0.00001334495,0.00004786495,0.00002996104,0.0000655033],"domain_scores_gemma":[0.9995556,0.00008061827,0.0001076524,0.00004436219,0.00002802632,0.0001837896],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7736319,0.03437161,0.0279009,0.00159956,0.005904825,0.0003885506,0.0002899439,0.0030342,0.02409235,0.0003932106,0.006939653,0.1214534],"study_design_scores_gemma":[0.7246739,0.2042811,0.0568333,0.0001150081,0.003504048,0.0004588924,0.0001289547,0.001352643,0.002366719,0.0003382547,0.00588998,0.00005725691],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933142,0.003129322,0.0002173855,0.0005765818,0.00009255677,0.00051958,0.0007271993,0.00003365384,0.001389432],"genre_scores_gemma":[0.9892458,0.00399643,0.0006646864,0.00107018,0.000192149,0.0009083847,0.001883586,0.00001846198,0.002020325],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002384722,"threshold_uncertainty_score":0.007977664,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07670647370780202,"score_gpt":0.3305121050339059,"score_spread":0.2538056313261038,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}